{
    "clinical_study": {
        "@rank": "143095", 
        "arm_group": {
            "arm_group_label": "CLL patients on Mabthera (rituximab)"
        }, 
        "brief_summary": {
            "textblock": "This study will examine the effectiveness of MabThera therapy added to a standard\n      chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia\n      (CLL). Patients who have received a single prior MabThera plus chemotherapy treatment are\n      eligible. The overall response rate of patients treated for approximately 5 months (as per\n      current label guidelines) will be analysed according to various factors (i.e., age,\n      concurrent treatment, and chromosomal abnormalities)."
        }, 
        "brief_title": "An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with first-line CLL having received only 1 cycle of MabThera chemotherapy\n\n          -  aged >/= 18 years\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding\n\n          -  Receipt of an investigational drug within 30 days prior to entering the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with untreated chronic lymphocytic leukemia (CLL)"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080884", 
            "org_study_id": "ML29201"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "number_of_groups": "1", 
        "official_title": "A MULTICENTER NON-INTERVENTIONAL STUDY EVALUATING THE BENEFIT OF THE COMBINATION OF MABTHERA (RITUXIMAB) WITH STANDARD CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN HUNGARY", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML29201 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "HUNGARY: Gyogyszereszeti \u00e9s Egeszsegugyi Minoseg- es Szervezetfejlesztesi Intezet Orszagos Gyogyszereszeti Intezet"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate (ORR) as assessed by the investigator using routine assessment techniques", 
            "safety_issue": "No", 
            "time_frame": "7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ORR analysed according to concomitant chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "7 months"
            }, 
            {
                "measure": "ORR analysed according to age", 
                "safety_issue": "No", 
                "time_frame": "7 months"
            }, 
            {
                "measure": "ORR analysed according to CIRS score", 
                "safety_issue": "No", 
                "time_frame": "7 months"
            }, 
            {
                "measure": "ORR analysed according to certain chromosomal abnormalities", 
                "safety_issue": "No", 
                "time_frame": "7 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}